Sinovac Biotech’s fully human anti-tetanus monoclonal antibody SNA02-48
injection has entered a Phase III trial, with the first volunteer enrolled at
Shenzhen Second People’s Hospital. SNA02-48 was cleared for clinical use in
March 2025 and is a recombinant fully human mAb for emergency post-exposure
prophylaxis against tetanus. Sinovac is expanding a wound-care portfolio
covering active and passive immunity: its adsorbed tetanus vaccine is
market-approved; Sinovac-backed Xingmeng Biotech’s Class 1 innovative drug
Krebi® (monoclonal antibody injection) is approved for passive immunization of
adults exposed to rabies; Sinovac’s lyophilized human rabies vaccine (serum-free
Vero cell) is in the regulatory filing stage.
